EcoDrugPlus

Matrix Metallopeptidase 2

Ensembl ID : ENSLBEG00000011830
Gene Symbol: MMP2
3 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSLBEG00000015615
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSLBEG00000002548
Gene Symbol: LOC109997114
3 Cross references
196 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSLBEG00000001654
Gene Symbol: LOC109988782
3 Cross references
198 Possible Orthologues:

Matrix Metalloproteinase-20-Like

Ensembl ID : ENSLBEG00000017925
Gene Symbol: LOC109992098
2 Cross references
163 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSLBEG00000014115
Gene Symbol: MTOR
3 Cross references
216 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSLBEG00000007944
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSLBEG00000006580
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSLBEG00000020899
Gene Symbol: LOC109992267
2 Cross references
215 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSLBEG00000001653
Gene Symbol: MTNR1A
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSLBEG00000023562
Gene Symbol: MME
4 Cross references
231 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSLBEG00000020644
Gene Symbol: LOC109980610
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).